Rallybio Corporation

Rallybio Corporation

NNASDAQ:RLYB
15.43
USD
-0.29
(-1.88%)
4.77EPS
3.59P/E
91.73MMarket Cap
Mar 11Next Earn
Rallybio Corporation
NASDAQ:RLYB
(Nasdaq Stock Market)

Recent

price

15.43

P/E

ratio

3.59

div

yld

- -

ROIC.AI

2019
2020
2021
2022
2023
2024
2025
TTM
USD
- -
- -
- -
- -
- -
0.12
0.15
0.08
Revenue per Share
-8.08
-9.51
-14.74
-16.76
-14.75
-10.61
-1.59
4.79
Basic EPS, GAAP
-7
-7.98
-14.38
-14.41
-11.92
-9.05
-5.3
5.54
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-5.28
35.38
43.72
35.8
22.46
11.88
10.97
17.31
Book Value per Share
-5.28
35.38
43.72
35.8
22.46
11.88
10.97
17.31
Tangible Book Value per Share
2
3
3
4
5
5
6
6
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
1
1
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
-9,511.95
-3,853.61
-5,580.88
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
-18
-26
-47
-67
-75
-58
-9
27
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
4.98
Effective Tax Rate (%)
- -
- -
- -
- -
- -
-9,084.12
-1,046.39
6,177.42
Profit Margin (%)
17
135
174
169
106
62
57
91
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
-20
136
176
169
106
62
58
92
Total Equity
- -
- -
- -
- -
- -
- -
- -
-29.34
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
34.48
Return on Capital (%)
- -
- -
-30.17
-38.65
-54.13
-68.85
-15.01
34.52
Return on Common Equity (%)

Capital Structure

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
5
5
5
Market Capitalization
47
85
92

Working Capital

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
53
97
95
Cash, Cash Equivalents & STI
47
93
91
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
4
4
3
Payables & Accruals
3
3
2
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-11.94%
-6%
Free Cash Flow
- -
15.84%
-39.51%
Net Income, GAAP
- -
4.89%
-84.46%
Sales/Revenue/Turnover
- -
- -
34.91%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
1
2025
- -
- -
- -
- -
1
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-3.73
-2.94
-2.06
-1.98
-10.61
2025
-1.69
-1.73
2.84
-1.11
-1.59
2026
-1.46
7.66
-0.48
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company founded in 2018 and headquartered at 234 Church Street in New Haven, Connecticut, develops transformative therapies for patients with severe rare diseases, focusing on areas of complement dysregulation and hematology; its lead product candidate, RLYB116, comprises a differentiated C5 inhibitor Affibody-ABD fusion protein in confirmatory pharmacokinetic/pharmacodynamic studies targeting immune platelet transfusion refractoriness and refractory antiphospholipid syndrome, while RLYB332 represents a preclinical long-acting matriptase-2 inhibitor monoclonal antibody for diseases of iron overload and severe anemias, RLYB114 includes a pegylated C5 inhibitor Affibody for ophthalmological complement dysregulation disorders, and the pipeline encompasses an undisclosed metabolic disease program. Rallybio operates primarily in the United States with global partnerships and targets patient populations underserved by current treatments in maternal-fetal health, immuno-inflammation, and metabolic disorders. In July 2025, the company sold its interest in the REV102 ENPP1 inhibitor program for hypophosphatasia—stemming from a prior joint venture with Recursion Pharmaceuticals—to Recursion for up to $25 million including a $7.5 million upfront equity payment, extending its cash runway into mid-2027 and sharpening focus on core pipeline assets; earlier in 2025, Rallybio discontinued development of RLYB212 following Phase 2 results in fetal and neonatal alloimmune thrombocytopenia prevention, while advancing natural history studies and planning key readouts for RLYB116.

Company News

  • Correction to Press Release Announcing Reverse Stock Split of Rallybio Common Stock in Connection with the Proposed Merger with Avenzo

  • Rallybio Announces Reverse Stock Split of Common Stock in Connection with the Proposed Merger with Avenzo

  • Rallybio Stockholders Approve Avenzo Merger, Name Change and Reverse Split

  • Rallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Rallybio Corporation - RLYB

  • Rallybio (NASDAQ:RLYB) Stock Price Up 1.9% – Should You Buy?

  • Are DXLG, LAB, FHB, RLYB Obtaining Fair Deals for their Shareholders?

  • Are DXLG, LAB, FHB, RLYB Obtaining Fair Deals for their Shareholders?

  • Are SUNE, RLYB, ASRT, TMHC Obtaining Fair Deals for their Shareholders?

  • Are SUNE, RLYB, ASRT, TMHC Obtaining Fair Deals for their Shareholders?

  • Rallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Rallybio Corporation - RLYB

  • Rallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Rallybio Corporation - RLYB

  • Shareholder Alert: Ademi LLP investigates whether Rallybio Corporation is obtaining a Fair Price for Public Shareholders

  • Rallybio Corporation (RLYB) M&A Call Prepared Remarks Transcript

  • RLYB Stock Alert: Halper Sadeh LLC is Investigating Whether Rallybio Corporation is Obtaining a Fair Price for its Shareholders

  • RLYB Stock Alert: Halper Sadeh LLC is Investigating Whether Rallybio Corporation is Obtaining a Fair Price for its Shareholders

  • Rallybio Corporation and Avenzo Therapeutics Announce Merger Agreement to Advance Next-Generation Oncology Therapies and $215 Million Concurrent Private Placement

  • Are WSR, TERN, RLYB, DAWN Obtaining Fair Deals for their Shareholders?

  • Are EWCZ, STEL, RLYB, CTRA Obtaining Fair Deals for their Shareholders?

  • $HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger—EWCZ, STEL, RLYB, and CTRA

  • $HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger—ALIS, TALK, JTAI, and RLYB